Influenza Vaccine Market Size, Share, Competitive Landscape and Trend Analysis Report, by Vaccine Type, Technology, Age Group and Route of Administration : Global Opportunity Analysis and Industry Forecast, 2021-2030

Influenza Vaccine Market Research, 2030

An influenza vaccine is a vaccine designed to protect against the influenza virus, commonly known as the flu, which comes in trivalent or quadrivalent types, used to treat seasonal and pandemic flu. It is based on egg-based and cell-based technology, used for adults and pediatric as well.

Market Value Projections and Insights

• The global influenza vaccine market size was valued at $5024.60 million in 2020, and is projected to reach $10,127.0 million by 2030, registering a CAGR of 7.20% from 2021 to 2030.
• By vaccine type, quadrivalent segment accounted for nearly 63% share of the influenza vaccine market in 2020.
• By technology, the egg-based segment is expected to grow at a CAGR of 7.7% from 2021 to 2030.
• By age group, the adult segment held largest market share in 2020 and is expected to remain dominant throughout the forecast period.
• By route of administration, the injection segment expected to grow at a CAGR from 2021 to 2030.
• By region, North America is expected to provide lucrative market growth opportunities and grow at a CAGR of 6.9% from 2021 to 2030.

The influenza vaccine market is experiencing significant growth, driven by key trends, challenges, and opportunities. Rising public awareness of the benefits of vaccination has spurred demand for flu vaccines. Government campaigns and healthcare providers are promoting vaccination to prevent seasonal flu outbreaks. Innovations such as recombinant and cell-based vaccines offer more efficient and effective flu prevention, providing better protection against virus mutations. These technologies are gaining traction, replacing traditional egg-based vaccine production. The main market driver is the growing geriatric population who are at higher risk of complications from the flu, making them a key target demographic. As the global population ages, there is a rising need for flu vaccines, especially in developed & developing nations.

Furthermore, governments worldwide are focusing on increasing vaccination rates to reduce the burden of influenza on healthcare systems. Subsidies and free flu shots in several countries drive higher vaccination uptake. However, global vaccine production faces challenges, including supply chain disruptions and storage requirements. The need for cold storage and efficient distribution hampers accessibility in remote areas. Moreover, expanding healthcare infrastructure and rising income levels in emerging economies present opportunities for increased vaccine adoption.

Industry Highlights

• The demand for influenza in the pharmaceutical sector is primarily driven by government initiatives and public health campaigns have bolstered vaccination rates, making vaccines more accessible through subsidies and free vaccination programs.
• Retail & Specialty Pharmacies, serve as key distribution channels, providing widespread access to influenza vaccines, especially during flu seasons.
• There is a heightened public awareness of flu prevention, particularly in light of global pandemic preparedness efforts.
• North America remains the leading regional market for influenza vaccines due to its advanced healthcare infrastructure and high consumer demand.

Influenza vaccines have long been essential for seasonal flu prevention, valued for their ability to protect vulnerable populations, particularly the elderly, children, and individuals with underlying health conditions. This makes them a critical component of public health strategies. Advanced flu vaccine formulations, such as recombinant and cell-based vaccines, are increasingly recognized for their ability to offer improved efficacy and faster production times, especially in response to emerging flu strains. High demand for influenza vaccines is driven by their proven effectiveness in reducing flu-related hospitalizations, which is particularly important during flu season peaks and in the context of global pandemic preparedness. Innovative vaccine technologies, such as adjuvanted or quadrivalent vaccines, offer broader protection against multiple flu strains, attracting both healthcare providers and consumers focused on comprehensive flu prevention. Healthcare systems across the world prioritize flu vaccination campaigns, with many governments offering free or subsidized flu shots to encourage high vaccination rates and reduce the burden on healthcare facilities during peak seasons.

Key Areas Covered in the Report

• Influenza vaccines are essential for public health due to their critical role in preventing seasonal flu outbreaks and protecting vulnerable populations like the elderly, children, and individuals with chronic conditions.
• The market faces competition from emerging technologies such as antiviral medications and new therapies.
• Innovations in vaccine technology, such as cell-based and recombinant vaccines, have added diversity and enhanced efficacy to the market, offering alternatives to traditional egg-based flu vaccines.
• Consumer preferences are evolving, with a growing demand for vaccines that offer broader protection (e.g., quadrivalent vaccines) and fewer side effects, driven by increased awareness of health and preventive care.
• Supply chain and distribution challenges remain a key issue, particularly in emerging markets, where logistical barriers and cold chain requirements complicate vaccine access and timely distribution.

The influenza vaccine market faces competition from evolving preventive health strategies, including antiviral medications and alternative therapies. However, the growing awareness of the importance of vaccination, particularly following the COVID-19 pandemic, has reinforced the demand for flu vaccines. Technological advancements, such as cell-based and recombinant vaccines, offer improved efficacy, addressing the challenge of flu virus mutations. These innovations allow for more tailored protection, increasing consumer preference for vaccines that offer broader or longer-lasting immunity. Additionally, governments and public health agencies are playing a key role by heavily investing in vaccination campaigns to enhance accessibility and reduce flu-related hospitalizations. The rising demand for quadrivalent vaccines, which protect against multiple strains, reflects the growing consumer desire for comprehensive coverage.

Topics discussed in the report

• Technological advancements in vaccine production
• Increasing government vaccination initiatives
• Emerging markets for influenza vaccines
• Quadrivalent vs. trivalent vaccines
• Role of public health campaigns
• Universal flu vaccine research and development

Segment Overview

The influenza vaccine market is segmented into vaccine type, technology, age group, route of administration and region. By vaccine type, it is divided into quadrivalent and trivalent. By technology, it is classified into egg-based and cell-based. By age group, it is divided into pediatric and adult. By route of administration, it is categorized into injection and nasal spray. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The quadrivalent type segment was the major revenue contributor, owing to its ability to immunize four influenza virus strains (two A subtypes and two B subtypes — H1N1 and H3N2 and Victoria and Yamagata, respectively).  The egg-based technology dominates the technology segment as it is most commonly used in production of both inactivated and live-attenuated vaccines. The adult age group segment was the highest contributor in the influenza vaccine market in 2020 and is expected to remain dominant during the forecast period, owing to higher risks of developing serious complications from influenza due to weaker immune response.  North America accounted for the largest influenza vaccine market share in 2020 and is expected to retain its dominance throughout the forecast period. This is attributed to the increased prevalence of influenza in the region, increase in government focus on immunization programs, emergence of new vaccines, and growth in technological advancements for vaccine administration.

Comparative Matrix of Key Segments

Regional Dynamics and Competition

Influenza vaccine market has witnessed significant growth and is expected to retain this trend throughout the  forecast  period.  This  is  attributed to  the  rise in  the  incidence  rate  of  influenza  across  the  globe  and increase in awareness about vaccination among the population. The vaccine market for influenza in developed countries, such as the  U.S., Germany, and Japan, accounts for the major market share; however, emerging economies such as India, China, Africa, Turkey, and others are also showing  significant  growth.  Growth  in  these  regions  is  due  to  high  unmet  demand  for  vaccines  and  newer influenza cases. Moreover, vaccines that are under phase III trials such as FLU-IGIV and Torlak-300, which are in pipeline and need to be approved, possess high market potential in emerging economies. Along with this, NIH’s universal influenza vaccine and Sanofi Pasteur’s Quadrivalent Influenza Vaccine is also being developed

Some of the key players operating in the influenza vaccine market are AstraZeneca plc., Biodiem, CSL Limited, Emergent BioSolutions, F. Hoffmann-La Roche Ltd., Gamma Vaccines Pty Ltd., GlaxoSmithKline plc, Merck & Co. Inc. (Merck Sharp & Dohme Corp.), Novartis AG, Pfizer, Inc., Sanofi Pasteur SA, and Sinovac Biotech Ltd.

Influenza vaccine Market News Release

• According to U.S. Department of Health & Human Services during 2019-2020 flu vaccination prevented an estimated 100,000 flu-related hospitalizations.
• In March 2021, Sanofi announced an investment of more than €600 million in a new vaccine manufacturing facility at its  existing  site  in  Canada.  This investment  in  a  new  facility  will  give  additional  antigen  and  filling capacity for Sanofi’s fluzone high-dose  quadrivalent  influenza  vaccine,  to  improve  supply  availability  in Canada, the U.S., and Europe.
• In February 2020, BioDiem Ltd. announced the approval of changchun BCHT biotechnology co. (BCHT)’s LAIV vaccine in china by the Chinese national medical products administration (NMPA), formerly known as the Chinese FDA.
• The popularity of quadrivalent vaccines is growing.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the influenza vaccine market analysis from 2021 to 2030 to identify the prevailing influenza vaccine market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the influenza vaccine market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global influenza vaccine market trends, key players, market segments, application areas, and market growth strategies.

  Influenza Vaccine Market Report Highlights

Aspects	Details
By VACCINE TYPE	VACCINE TYPE Trivalent
By TECHNOLOGY	Egg-based Egg-based
By AGE GROUP	Pediatric Adult
By ROUTE OF ADMINISTRATION	Injection Nasal spray
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players	SANOFI, CSL LIMITED (SEQIRUS GMBH), ASTRAZENECA PLC (ASTRAZENECA), GLAXOSMITHKLINE PLC, PFIZER, INC., EMERGENT BIOSOLUTIONS INC., BIODIEM LTD, MERCK & CO., INC. (MERCK SHARP & DOHME CORP.), GAMMA VACCINES PTY LTD., HOFFMANN-LA ROCHE LTD.

Analyst Review

According to analyst perspective, the influenza vaccine industry holds the maximum potential, owing to the increase in R&D activities related to influenza vaccines, growth in immunization programs, and rise in the incidences of influenza globally which, in turn, are responsible to drive the market growth. Furthermore, significant technological advancements in the manufacturing technology of vaccines to improve efficacy and potency of vaccines along with increased investments by manufacturers to upgrade traditional vaccination production and delivery methods contribute to increased profit margins and enhanced operational efficiencies in the production of influenza vaccines, especially in the U.S. Novel vaccine development generally takes about 10-15 years to develop and establish its safety and efficacy which is a huge process and regulatory requirements for clinical trials vary in countries may delay in development of vaccines which is projected to limit the growth of the market.

Author Name(s) : Vishal Bhardwaj| Ajinkya Alhat| Shubham Choudante | Roshan Deshmukh

Related Tags

• Infectious Diseases
• Drug Delivery
• Cancer Drugs